---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018467"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:18:22.842405+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Axsome Q1 2023: Auvelity sales $15.7M, total revenue $94.6M, net loss narrows to $11.2M

## Summary
- Auvelity net product sales $15.7M in first full quarter; ~31,000 prescriptions, up 298% vs Q4 2022.
- Total Q1 revenue $94.6M including $65.7M upfront from Sunosi ex-U.S. license to Pharmanovia; net loss $(11.2)M ($0.26/sh) vs $(39.6)M ($1.03/sh) a year ago.
- Sunosi net sales $12.9M (U.S. $11.2M, int'l $1.7M); U.S. prescriptions up 13% YoY and 4% sequentially.
- Amended Hercules term loan to $350M with reduced rate, extended maturity; cash $246.5M at March 31.
- Pipeline milestones: AXS-12 Phase 3 narcolepsy topline Q2 2023; AXS-07 migraine NDA resubmission 2H 2023; AXS-14 fibromyalgia NDA submission Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-018467
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/0000950170-23-018467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/axsm-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018467
- JSON: https://secwatch.observer/filing/0000950170-23-018467.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018467.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $94.6 million, net income net loss of $11.2 million, EPS $(0.26) per share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $94.6 million
  - Net income: net loss of $11.2 million
  - EPS: $(0.26) per share
  - Result: reported results
  source text: 2023 Financial Results and Corporate Update Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 8, 2023 (GLOBE NEWSWIRE) -- Axsome
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/0000950170-23-018467-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.